Head to Head Survey: BioRestorative Therapies (OTCMKTS:BRTX) versus PHAXIAM Therapeutics (NASDAQ:PHXM)

BioRestorative Therapies (OTCMKTS:BRTX) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Institutional and Insider Ownership

69.4% of BioRestorative Therapies shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 21.6% of BioRestorative Therapies shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares BioRestorative Therapies and PHAXIAM Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	-13,728.83%	-120.47%	-114.48%
PHAXIAM Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares BioRestorative Therapies and PHAXIAM Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioRestorative Therapies	$145,800.00	62.22	-$18.50 million	($3.51)	-0.38
PHAXIAM Therapeutics	$32.66 million	0.32	-$240,000.00	N/A	N/A

PHAXIAM Therapeutics has higher revenue and earnings than BioRestorative Therapies.

Analyst Recommendations

This is a summary of current ratings and price targets for BioRestorative Therapies and PHAXIAM Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioRestorative Therapies	0	0	1	0	3.00
PHAXIAM Therapeutics	0	0	0	0	N/A

BioRestorative Therapies presently has a consensus target price of $15.00, suggesting a potential upside of 1,019.40%. Given BioRestorative Therapies’ higher probable upside, analysts clearly believe BioRestorative Therapies is more favorable than PHAXIAM Therapeutics.

Risk & Volatility

BioRestorative Therapies has a beta of 61.54, indicating that its stock price is 6,054% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.

Summary

BioRestorative Therapies beats PHAXIAM Therapeutics on 6 of the 11 factors compared between the two stocks.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

About PHAXIAM Therapeutics

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.